Steroids remain the first-choice therapeutic in sarcoidosis; however, long-term use is associated with toxicity. Evidence defining the best second-line therapeutic is currently lacking. The aim of this study was to compare the effect of methotrexate and azathioprine on prednisone tapering, pulmonary function, and side effects in the second-line treatment of sarcoidosis.status: publishe
Background: Side effects limit the long-term use of glucocorticoids in cardiac sarcoidosis (CS), and...
About half of patients with sarcoidosis will need systemic therapy for their disease. Oral glucocort...
Sarcoidosis is a multisystem disorder of unknown cause with a highly variable course. Corticosteroid...
Background: Methotrexate (MTX) is a second line agent for treatment of sarcoidosis. Its long term sa...
Background: There is insufficient information in the literature on the comparative efficacy and tole...
The main goal of this thesis was to investigate various second and third-line systemic therapeutic o...
Item does not contain fulltextPURPOSE OF REVIEW: Although glucocorticosteroids are considered the fi...
Background: Immunosuppressive and cytotoxic agents have been used as both an alternative to oral cor...
Among those who study granulomatous diseases, sarcoidosis is of tremendous interest, not only becaus...
Corticosteroids are still the cornerstone of treatment for patients with sarcoidosis requiring syste...
The objective of this study is to conduct a comparative study of the efficacy and safety of methotre...
ABSTRACT: The treatment options for pulmonary sarcoidosis have increased over the past 10 years. As ...
The objective of this study is to conduct a comparative study of the efficacy and safety of methotre...
SummaryBackgroundImmunosuppressive (IS) therapy is indicated to treat progressive sarcoidosis, but r...
SummaryBackgroundMost issues concerning pharmacotherapy of pulmonary sarcoidosis have not been resol...
Background: Side effects limit the long-term use of glucocorticoids in cardiac sarcoidosis (CS), and...
About half of patients with sarcoidosis will need systemic therapy for their disease. Oral glucocort...
Sarcoidosis is a multisystem disorder of unknown cause with a highly variable course. Corticosteroid...
Background: Methotrexate (MTX) is a second line agent for treatment of sarcoidosis. Its long term sa...
Background: There is insufficient information in the literature on the comparative efficacy and tole...
The main goal of this thesis was to investigate various second and third-line systemic therapeutic o...
Item does not contain fulltextPURPOSE OF REVIEW: Although glucocorticosteroids are considered the fi...
Background: Immunosuppressive and cytotoxic agents have been used as both an alternative to oral cor...
Among those who study granulomatous diseases, sarcoidosis is of tremendous interest, not only becaus...
Corticosteroids are still the cornerstone of treatment for patients with sarcoidosis requiring syste...
The objective of this study is to conduct a comparative study of the efficacy and safety of methotre...
ABSTRACT: The treatment options for pulmonary sarcoidosis have increased over the past 10 years. As ...
The objective of this study is to conduct a comparative study of the efficacy and safety of methotre...
SummaryBackgroundImmunosuppressive (IS) therapy is indicated to treat progressive sarcoidosis, but r...
SummaryBackgroundMost issues concerning pharmacotherapy of pulmonary sarcoidosis have not been resol...
Background: Side effects limit the long-term use of glucocorticoids in cardiac sarcoidosis (CS), and...
About half of patients with sarcoidosis will need systemic therapy for their disease. Oral glucocort...
Sarcoidosis is a multisystem disorder of unknown cause with a highly variable course. Corticosteroid...